Coronary stent

Coronary Stents (Cardiovascular) - Global Market Analysis and Forecast Model 2022 Report: Key Players Include Boston Scientific, Medtronic & Meril Life Sciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022

Coronary Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

Key Points: 
  • Coronary Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Coronary Stents market for the year 2020 and beyond.
  • The Coronary Stents Market is segmented into Bare Metal Stents, Drug Eluting Stents (DES), Covered Stents, Bioabsorbable Stents (BAS).
  • Key Inclusions of the market model are:
    Currently marketed Coronary Stents market and evolving competitive landscape:
    Insightful review of the key industry trends.

Philips announces first patient enrollment in DEFINE GPS global multicenter study to assess superiority of PCI procedures guided by co-registered iFR and interventional angiography

Retrieved on: 
Tuesday, June 22, 2021

DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.

Key Points: 
  • DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.
  • With DEFINE GPS we will be able to definitively determine if a physiology-based PCI approach results in superior patient outcomes compared to standard angioplasty.
  • The DEFINE GPS study is sponsored by Philips, with the Cardiovascular Research Foundation overseeing core lab and clinical event committee activities.
  • The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.

CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave’s Coronary IVL

Retrieved on: 
Friday, June 11, 2021

In the July 2021 Update of the Hospital Outpatient Prospective Payment System (OPPS), CMS issued a new device transitional pass-through code (C1761) for use by hospitals to bill for Shockwave C2 Coronary IVL catheters.

Key Points: 
  • In the July 2021 Update of the Hospital Outpatient Prospective Payment System (OPPS), CMS issued a new device transitional pass-through code (C1761) for use by hospitals to bill for Shockwave C2 Coronary IVL catheters.
  • In addition, as part of the payment calculation, CMS announced that a customary deduction known as a device offset will not be applied to coronary stenting procedures involving coronary IVL.
  • The Shockwave C2 Coronary IVL device will be eligible for TPT payments for three years.
  • This announcement comes less than two months after CMS recommended Coronary IVL be eligible for incremental payment via a New Technology Add-on Payment (NTAP) as part of the Fiscal Year 2022 Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule.

DHR Health and Cipherome to Pioneer Personalized Medicine Project in Patients Undergoing Percutaneous Coronary Interventions

Retrieved on: 
Sunday, February 28, 2021

After a stroke or heart attack, the standard treatment is Percutaneous Coronary Intervention (PCI), or stent placement.

Key Points: 
  • After a stroke or heart attack, the standard treatment is Percutaneous Coronary Intervention (PCI), or stent placement.
  • Recent studies show the possibility of an 80-percent reduction in PCI 90-day complications by using a patients personalized genetic information.
  • About DHR Health Institute for Research and Development:
    DHR Health Institute for Research & Development is a nonprofit organized under the Federal Internal Revenue Service Code 501(c)(3).
  • DHR Health Institute for Research and Development leads the way for innovative state-of-the-art clinical research in the Rio Grande Valley.

Global Drug-device Combination Product Markets Report 2020: Technology Roadmap and Growth Opportunity - Drug-eluting Stents, Drug-eluting Contact Lens, Drug-eluting Bandages, & Orthopedic Implants

Retrieved on: 
Friday, February 5, 2021

3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity

Key Points: 
  • 3.2.6 Moderate to Low Patent Activity of Drug-eluting Contact Lens with Johnson & Johnson Vision Care Inc., Showing High Activity
    4.2 Future of Coronary Stents: Gene Eluting Stents to Overcome Restenosis and Late-stent Thrombosis Challenges
    4.6 Business Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Therapy
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

SpectraWAVE Announces $13.2 Million Series A-2 Financing from Existing Investors to Bring Intracoronary Imaging Technology to Market

Retrieved on: 
Wednesday, February 3, 2021

today announced a $13.2 million Series A-2 financing to support completion of product development and regulatory filing for its flagship intracoronary imaging product, designed to help physicians optimize coronary stenting interventions and limit future adverse events.

Key Points: 
  • today announced a $13.2 million Series A-2 financing to support completion of product development and regulatory filing for its flagship intracoronary imaging product, designed to help physicians optimize coronary stenting interventions and limit future adverse events.
  • The funding round is led by prior investor Deerfield Management, and includes follow-on investment from prior unnamed seed investors.
  • In CAD, patients can undergo stent placement to relieve symptoms, but one in five patients can experience a major adverse event.
  • SpectraWAVE is developing a medical imaging platform that combines two state-of-the-art technologies providing high resolution plaque structure and content in coronary blood vessels.

India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents - ResearchAndMarkets.com

Retrieved on: 
Monday, January 25, 2021

The "India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.
  • "India Interventional Cardiology Market Outlook to 2025" is a comprehensive databook report, covering key market data on the India Interventional Cardiology market.
  • The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS) and PTCA Balloon Catheters.
  • Global corporate-level profiles of key companies operating within the India Interventional Cardiology Market.

Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Retrieved on: 
Wednesday, January 13, 2021

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.

Key Points: 
  • Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.
  • We are enthusiastic about leading this trial studying an important innovation in percutaneous coronary interventions, the bioadaptor, said Dr. Saito.
  • The DynamX Bioadaptor RCT is an important contribution to demonstrating the significant benefits our device offers for patients, said Motasim Sirhan, Elixir Medical CEO.
  • Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice.

Asia-Pacific Interventional Cardiology Market Outlook to 2025, with Focus on Cardiac Catheters, Coronary Guidewires, Coronary Stents and More - ResearchAndMarkets.com

Retrieved on: 
Monday, January 4, 2021

The "Asia-Pacific Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's

Key Points: 
  • The "Asia-Pacific Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's
    This is a comprehensive databook report, covering key market data on the Asia - Pacific Interventional Cardiology market.
  • The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS) and PTCA Balloon Catheters.
  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the Asia - Pacific Interventional Cardiology Market.

Small vessels can cause big problems; MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions

Retrieved on: 
Thursday, December 17, 2020

The proposed indication for use includes "The MagicTouch SCB Sirolimus Coated Balloon Catheter is indicated for percutaneous transluminal coronary angioplasty, after appropriate vessel preparation, of small coronary artery lesion lengths of 6 - 36mm in coronary arteries with reference vessel diameters of 1.50 - 2.75mm."

Key Points: 
  • The proposed indication for use includes "The MagicTouch SCB Sirolimus Coated Balloon Catheter is indicated for percutaneous transluminal coronary angioplasty, after appropriate vessel preparation, of small coronary artery lesion lengths of 6 - 36mm in coronary arteries with reference vessel diameters of 1.50 - 2.75mm."
  • Each of the three main arteries supplying blood to the cardiac musculature, branches into progressively smaller vessels that eventually penetrate the cardiac musculature.
  • This presence of angina with minimal or no angiographic CAD is referred to as Coronary Microvascular Dysfunction (CMD).
  • MagicTouch SCB Sirolimus coated balloon is developed using this Nanolute Technology for use in the treatment of small coronary artery lesions in CMD.